Expert Interview
Discussing Altimmune's GLP-1/glucagon dual receptor agonist candidate, pemvidutide, and the 48-week data from the Phase 2 MOMENTUM trial presented at the American Diabetes Association’s (ADA) 84th Scientific Sessions
Ticker(s): ALTInstitution: Mayo Clinic
- Endocrinologist and part of the Mayo Clinic Precision Medicine for Obesity program
- Treats over 1000 patients for obesity per year
- Clinical and research focus on understanding obesity's pathophysiology to develop more effective therapeutic interventions, especially for perimenopausal women and breast cancer survivors.
How do the results from the MOMENTUM trial compare to the efiicacy of other tirzepatide?
Added By: sara_adminIs pemvidutide different from the other GLP-1/glucagon dual receptor agonist candidates in development or on the market?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of pemvidutide, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
